In short
Clinical trials are studying GSKVX000000030825 in people with herpes simplex and in healthy adults. These studies look at safety, side effects after each dose, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy participants aged 18-40 years and participants aged 18-60 years with recurrent genital herpes.
Key points
- Clinical trials of GSKVX000000030825 are studying herpes simplex, especially recurrent genital herpes. The main trial is a Phase 1/2 study in healthy adults aged 18-40 years and in adults aged 18-60 years with recurrent genital herpes. The study looks at safety, short-term reactions after each dose, immune response, and possible efficacy. It also measures serious events, lab test changes, and the time to the first confirmed HSV-2 recurrence. One completed trial enrolled 515 participants.
Trial overview
The available trial for GSKVX000000030825 is Phase 1/2 and was designed to study reactogenicity, safety, immune response, and efficacy in herpes simplex.
The study was completed and enrolled 515 participants.
The trial focused on people with herpes simplex, especially those with recurrent genital herpes, and also included healthy participants.
Who the studies include
The study included healthy participants aged 18-40 years and participants aged 18-60 years with recurrent genital herpes.
This means the trial looked at both people without the condition and people who already had repeat genital herpes episodes.
What the trials measure
The trial measured solicited administration site events, which are expected local reactions after a dose, such as redness, pain, and swelling within 7 days after each dose.
It also measured solicited systemic events, which are whole-body reactions such as fever, fatigue, headache, muscle pain, and joint pain within 7 days after each dose.
Another endpoint was unsolicited adverse events, meaning any unwanted health problem reported within 28 days after each dose.
The study also tracked medically attended events, serious adverse events, and potential immune-mediated disorders from the first dose up to 12 months after the last study intervention.
Blood and chemistry tests were checked for haematological and biochemical laboratory abnormalities after doses in both parts of the study.
For efficacy, the study measured time to first confirmed HSV-2 recurrent genital herpes episode.
Trial design and comparison groups
The study was interventional, which means participants received study products rather than only being observed.
The intervention list included GSKVX000000030825, GSKVX000000030810, GSKVX000000030918, and NaCl solution, all given by intramuscular use in the trial record.
The brief summary states that the main aim was to evaluate the reactogenicity and safety of the HSVTI, and in Part II to show efficacy in reducing confirmed HSV-2 recurrent genital herpes episodes.
What the results may mean for patients
These trials are important because they do not only ask whether GSKVX000000030825 may help reduce herpes recurrences, but also whether it can be given safely.
By measuring local reactions, whole-body symptoms, lab changes, and longer-term serious events, the study gives a broad safety picture.
By measuring the time to the first confirmed HSV-2 recurrence, the study also looks at whether the treatment may delay the next outbreak in people with recurrent genital herpes.